Health Condition 1: null- Healthy individuals with cataract and astigmatism.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: • A patient with cataract for which phacoemulsification extraction and a posterior chamber IOL implantation has been planned • Male or female in good general health, 18 years of age or older at the time of the pre-operative examination • A patient has the visual potential of 20/25 or better in each eye after cataract removal and IOL implantation • A patient with preoperative corneal astigmatism of between 0.75D and 1.5D • A patient with no more than 1D difference in the amount of corneal astigmatism in each eye • A patient with clear ocular media other than cataract in each eye • A patient with normal OCT of the macula in each eye
Exclusion criteria
Exclusion criteria: • A patient with a known pathology that may affect visual acuity (as determined by the Investigator); particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) in either eye • A patient with amblyopia or strabismus • A patient with capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome) in either eye • A patient with visually significant Epithelial Basement Membrane Dystrophy on slit-lamp exam in either eye • A patient with evidence of Keratoconus or significant irregular astigmatism on pre-operative topography in either eye • A patient has a history of significant ocular trauma or prior ocular surgery in either eye • A patient that may or is expected to undergo surgical intervention and/or ocular laser treatment prior to or during the study period in either eye • A patient that had refractive surgery (LASIK, LASEK, RK, PRK, etc.) prior to cataract surgery in either eye • A patient that has been wearing PMMA lenses within 6 months, gas permeable lenses within one month, or extended-wear or daily soft contact lens within 7 days of their scheduled surgery • A patient that requires the use of systemic or ocular medications that may affect vision • A patient with any uncontrolled systemic disease. A potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study • A patient currently participating or has participated within 30 days prior to thestart of this study in a drug or other investigational research study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Residual astigmatism after surgery.Timepoint: Day 1, 15 and 3 month after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in aberrations and corneal topography.Timepoint: Day 1, 15 and 3 month after surgery. | — |
Countries
India
Contacts
Nethradhama Superspeciality eye hospital